Latest news with #Ryoncil
Yahoo
28-07-2025
- Business
- Yahoo
Mesoblast Limited (MESO) Launches First Cell Therapy for Children
We recently compiled a list of Mesoblast Limited stands tenth on our list and has launched the first cell therapy for children. Mesoblast Limited (NASDAQ:MESO) is among the best mid-cap stocks to buy according to billionaires. It is a global leader in developing allogeneic (off-the-shelf) cellular medicines using its proprietary mesenchymal lineage cell technology. The company targets severe inflammatory diseases that lack effective treatment options. Its lead product, Ryoncil (remestemcel-L), became the first and only FDA-approved mesenchymal stromal cell therapy for children with steroid-refractory acute graft versus host disease (GVHD) in March 2025. Following approval, Mesoblast Limited (NASDAQ:MESO) rapidly launched the drug, partnering with over 25 major U.S. transplant centers and securing insurance coverage for over 250 million lives, including mandatory Medicaid coverage in all states. Ryoncil now benefits from seven years of orphan drug exclusivity and biologic exclusivity until 2036, with intellectual property protection through 2044, effectively limiting competition. The approval marks the foundation of the business's broader pediatric inflammatory disease franchise, with plans to expand Ryoncil's use to additional pediatric and adult indications. A healthcare professional examining T-cell immunotherapy. The corporation's manufacturing processes allow scalable production of consistent cell therapies without the need for donor-recipient matching, simplifying access and logistics. The company is also advancing other key candidates: Revascor (rexlemestrocel-L) for ischemic heart failure, which is on track for FDA submission by the end of 2025 under RMAT designation, and a Phase 3 program for rexlemestrocel-L targeting chronic discogenic low back pain, offering a non-opioid alternative for patients. While we acknowledge the potential of MESO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Sign in to access your portfolio
Sky News AU
21-07-2025
- Business
- Sky News AU
ASX 200 sheds more than $25 billion on Monday after surging about 2.3 per cent over late last week
The ASX 200 has sank on Monday, clawing back a massive surge late last week that pushed the index to new record highs. The index fell 0.8 per cent in the first 50 minutes of trading, wiping more than $25 billion off local investors' portfolios. It follows the index rising 0.9 per cent on Thursday and another 1.4 per cent on Friday Australian regenerative medicine company Mesoblast shed 7.9 per cent after surging more than 32 per cent on Friday when it revealed strong results from the commercial launch of children's drug Ryoncil. Regis Resources has shed four per cent, while Insignia Financial is down 5.3 per cent and Lifestyle Communities has sank 2.5 per cent. Buy-now-pay-later company Block, which is led by Twitter-founder Jack Dorsey and listed on the Nasdaq, jumped about 10.9 per cent after news emerged it would join the S&P 500. Other strong performers include AMP, which jumped 5.5 per cent after revealing a strong second-quarter performance, and Clarity Pharmaceuticals which is up 4.9 per cent. Investors await the RBA meeting minutes due on Tuesday which will reveal the thinking behind the central bank's shock rate hold. Josh Gilbert, a market analyst with trading platform eToro, said further explanation of the decision, which three of the nine RBA board members disagreed with, will be critical for a better understanding of Australia's economy. 'We know RBA chair Michele Bullock leans towards quarterly (inflation) readings, not the monthly ones, for a more stable indicator of economic health and that this caution likely motivated her to vote for a pause, but analysts will be keen to get a deeper understanding of the board's broader perspective,' Mr Gilbert said. It was a mixed bag on Wall Street on Friday with both the S&P 500 and the Nasdaq finishing flat while the Dow Jones sank 0.3 per cent. London's FTSE 250 Index jumped 0.6 per cent, Germany's DAX shed 0.3 per cent and the STOXX Europe 600 finished flat. New Zealand's NZX 50 Index is up 0.4 per cent since trading began on Monday while Japan's Nikkei 225 is down 0.2 per cent.
AU Financial Review
18-07-2025
- Business
- AU Financial Review
Mesoblast shares soar 35pc on strong cell therapy sales data
Biotech Mesoblast has reported strong initial sales of its cell therapy, Ryoncil, its first commercial product since the company was founded two decades ago, sending its shares soaring. The US Food and Drug Administration approved the therapy to treat children for complications that can occur during bone marrow transplants last December, paving the way for the first commercial sales in March.
Business Insider
18-07-2025
- Business
- Business Insider
Mesoblast reports Q1 Ryoncil gross revenue $13.2M
Mesoblast (MESO) announced gross revenue from sales of Ryoncil through the first quarter post product launch. Ryoncil is the first and only FDA approved mesenchymal stromal cell product in the Unites States and became commercially available for purchase on March 28, 2025, within one quarter of receiving FDA approval for treatment of steroid-refractory acute graft-versus-host disease in children. Mesoblast Chief Executive Dr. Silviu Itescu said, 'We are pleased with the commercial launch activities of Ryoncil in the first quarter post-launch and look forward to updating on the current quarter's progress now that mandatory state CMS coverage has become effective as of July 1, and we complete onboarding of the remaining major U.S. transplant centers.' Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with , delivered to your inbox every week.
Sky News AU
18-07-2025
- Business
- Sky News AU
ASX 200 continues to soar, adding to its record high after a boom on Wall Street
The ASX has surged again, tracking gains on Wall Street and continuing the momentum picked up on Thursday when it closed at a record high. The index has risen 0.7 per cent in the first 45 minutes of trading on Friday, adding more than $20b to local investors' portfolios. Best performers include major miners Iluka Resources (up 4.9 per cent), Pilbara Minerals (up 6.5 per cent) and Mineral Resources (up 4.4 per cent). Australian regenerative medicine company Mesoblast has surged about 20 per cent after revealing strong results from the commercial launch of children's drug Ryoncil. Mining giant BHP has jumped 1.8 per cent after revealing record copper and iron ore production in the 2025 financial year. RBC Capital Markets analyst Kaan Peker said he expects the 'stock to do well today' after the revelation. 'FY25 production guidance was achieved, with record iron ore production and two million tonnes of copper produced for the year,' Mr Peker said. Tech stocks have shined on Friday with family social media app-owner Life360 rising two per cent per cent, buy-now-pay-later company Block jumping 2.7 per cent and data centre owner Nextdc rising 1.5 per cent. Wall Street was in the green on Thursday with the Dow Jones and S&P 500 rising half a per cent while the Nasdaq jumped 0.8 per cent. London's FSTE 250 added 0.8 per cent, Germany's DAX lifted 1.5 per cent and the STOXX Europe 600 rose one per cent on Thursday. New Zealand's NZX 50 Index has slumped 0.1 per cent since trading began on Friday while Japan's Nikkei 225 is up 0.1 per cent.
